Figure 1From: Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study Pharmacodynamic effects of IL-21 at the 30 mcg/kg dose, as monotherapy (previous study [[22]]) versus in combination with sorafenib (current study). (A) Induction of serum sCD25, (B) Changes in peripheral blood absolute lymphocyte count (ALC).Back to article page